Patents by Inventor Camilla Bacci

Camilla Bacci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL2 IMMUNOCONJUQATE PREPARATION
    Publication number: 20250170262
    Abstract: The application relates to a preparation, in particular a pharmaceutical preparation, comprising a non-glycosylated IL2 immunoconjugate and a glycosylated IL2 immunoconjugate, wherein the percentage of the glycosylated IL2 immunoconjugate of the total IL2 immunoconjugate in the preparation is low, preferably 25% or lower. The preparation finds application in the treatment of cancer in human patients.
    Type: Application
    Filed: March 22, 2023
    Publication date: May 29, 2025
    Inventors: Paola BATTESTIN, Camilla BACCI, Alessandro REDI, Emiliano SANI, Ettore GILARDONI, Riccardo STUCCHI, Roberto DE LUCA, Cesare DI NITTO, Mattia MATASCI, Dario NERI
  • TNFALPHA IMMUNOCONJUGATE PREPARATION
    Publication number: 20250161475
    Abstract: The application relates to a preparation, in particular a pharmaceutical preparation, comprising a non-glycosylated TNF? immunoconjugate and a glycosylated TNF? immunoconjugate, wherein the percentage of the glycosylated TNF? immunoconjugate of the total TNF? immunoconjugate in the preparation is low, preferably 10% or lower. The preparation finds application in the treatment of cancer, such as brain tumors, in human patients.
    Type: Application
    Filed: March 21, 2023
    Publication date: May 22, 2025
    Inventors: Ettore GILARDONI, Paola BATTESTIN, Camilla BACCI, Alessandro REDI, Emiliano SANI, Riccardo STUCCHI, Roberto DE LUCA, Cesare DI NITTO, Mattia MATASCI, Dario NERI
  • Antibody compositions
    Patent number: 12023381
    Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: July 2, 2024
    Assignee: Philogen S.p.A.
    Inventors: Giovanni Neri, Camilla Bacci
  • DOSAGE UNITS AND REGIMEN, USES, METHODS OR FORMULATIONS OF COMPOSITIONS COMPRISING A RECOMBINANT PROTEIN COMPRISING INTERLEUKIN-12 AND AN ANTIBODY BINDING THE EXTRA-DOMAIN B OF FIBRONECTIN
    Publication number: 20230312726
    Abstract: The present invention relates to a dosage unit or regimen, recombinant protein for use, method or formulation of a recombinant protein comprising interleukin-12 (IL-12) and an antibody binding the extra-domain B (ED-B) of fibronectin, or a target binding fragment or derivative thereof.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 5, 2023
    Applicant: PHILOGEN S.P.A.
    Inventors: Camilla BACCI, Theresa HEMMERLE
  • ANTIBODY COMPOSITIONS
    Publication number: 20230165960
    Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.
    Type: Application
    Filed: May 25, 2022
    Publication date: June 1, 2023
    Applicant: Philogen S.p.A.
    Inventors: Giovanni Neri, Camilla Bacci
  • Antibody compositions
    Patent number: 11351257
    Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: June 7, 2022
    Assignee: PHILOGEN S.P.A.
    Inventors: Giovanni Neri, Camilla Bacci
  • Antibody Compositions
    Publication number: 20210093720
    Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.
    Type: Application
    Filed: June 14, 2017
    Publication date: April 1, 2021
    Inventors: Giovanni Neri, Camilla Bacci